Christopher Richard Anzalone - 07 Feb 2025 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Role
Chief Executive Officer, Director
Signature
/s/Christopher Anzalone
Issuer symbol
ARWR
Transactions as of
07 Feb 2025
Net transactions value
+$191,955
Form type
4
Filing time
10 Feb 2025, 18:23:16 UTC
Previous filing
06 Jan 2025
Next filing
05 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARWR Common Stock Award $191,955 +9,550 +0.25% $20.10 3,773,802 07 Feb 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares represent equity in lieu of part of his year-end cash bonus.
F2 Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.